These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26953277)
1. Companies use value-based pricing for single-source off-patent drugs. Thompson CA Am J Health Syst Pharm; 2016 Mar; 73(6):350, 352, 355. PubMed ID: 26953277 [No Abstract] [Full Text] [Related]
2. Pharmaceutical pricing conundrum: time to get rid of it? Garattini L; Padula A Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646 [No Abstract] [Full Text] [Related]
3. Pricing medicines: theory and practice, challenges and opportunities. Gregson N; Sparrowhawk K; Mauskopf J; Paul J Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076 [TBL] [Abstract][Full Text] [Related]
4. Patent office backlog adds billions to national drug expenditure. Gaudry KS; Cummings DE Nat Biotechnol; 2014 May; 32(5):436-9. PubMed ID: 24811513 [No Abstract] [Full Text] [Related]
5. Long way down--pharmaceutical companies fear falling off 'patent cliff'. Sklan A Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667 [No Abstract] [Full Text] [Related]
6. Towards universal health coverage in India. Phadke A; Bhargava A Lancet; 2011 May; 377(9777):1569. PubMed ID: 21550477 [No Abstract] [Full Text] [Related]
7. High cost of new drugs. Mazzucato M BMJ; 2016 Jul; 354():i4136. PubMed ID: 27815284 [No Abstract] [Full Text] [Related]
8. Diversity of Participants in the 340B Drug Pricing Program for US Hospitals. Nikpay S; Buntin M; Conti RM JAMA Intern Med; 2018 Aug; 178(8):1124-1127. PubMed ID: 29799997 [TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical R&D: an age of change? Baldwin JJ Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132 [No Abstract] [Full Text] [Related]
10. Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting? Garattini L; Padula A J R Soc Med; 2020 Mar; 113(3):93-97. PubMed ID: 31858868 [No Abstract] [Full Text] [Related]
12. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? Sarpatwari A; Kesselheim AS PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662 [TBL] [Abstract][Full Text] [Related]
13. Cheap drugs? Part 1: a challenge to multinationals and to patent rights. Ann Oncol; 2001 Apr; 12(4):423-4. PubMed ID: 11398867 [No Abstract] [Full Text] [Related]
14. Reference pricing of pharmaceuticals. Brekke KR; Königbauer I; Straume OR J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769 [TBL] [Abstract][Full Text] [Related]
15. Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications. Huskamp HA; Shinogle JA Psychiatr Serv; 2005 Sep; 56(9):1056-8. PubMed ID: 16148317 [No Abstract] [Full Text] [Related]
16. Going over the patent cliff. Schommer JC Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283 [No Abstract] [Full Text] [Related]
18. Strategic options for brand-name prescription drugs when patents expire. Mehta SC; Mehta SS Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309 [TBL] [Abstract][Full Text] [Related]
19. Patent nonsense: evidence tells of an industry out of social control. Mintzberg H CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900 [No Abstract] [Full Text] [Related]
20. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies]. Castillo-Laborde C; Silva-Illanes N Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]